Compare DAN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | EWTX |
|---|---|---|
| Founded | 1904 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2002 | 2021 |
| Metric | DAN | EWTX |
|---|---|---|
| Price | $30.40 | $44.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $40.60 | $39.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 264.10 | N/A |
| EPS | ★ 9.93 | N/A |
| Revenue | ★ $7,500,000,000.00 | N/A |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $4.59 | N/A |
| P/E Ratio | $3.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.74 | $13.38 |
| 52 Week High | $39.56 | $48.40 |
| Indicator | DAN | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 59.86 |
| Support Level | $25.49 | $37.50 |
| Resistance Level | $31.73 | $48.40 |
| Average True Range (ATR) | 1.27 | 2.27 |
| MACD | 0.46 | 0.39 |
| Stochastic Oscillator | 86.00 | 89.89 |
Dana Inc is provider of products to virtually every vehicle manufacturer in the world. Its technologies include drive systems (axles, driveshafts and transmissions); electrodynamic technologies (motors, inverters, software and control systems, battery-management systems, and fuel cell plates); sealing solutions (gaskets, seals, cam covers, and oil pan modules); thermal-management technologies (transmission and engine oil cooling, battery and electronics cooling, charge air cooling, and thermal-acoustical protective shielding); and digital solutions (active and passive system controls and descriptive and predictive analytics). The company has two operating segments: Light Vehicle and Commercial Vehicle. The Light Vehicles segment generates the majority of revenue.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.